WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 11, 596-605. Review Article ISSN 2277–7105

A REVIEW OF MOLECULAR DOCKING INVESTIGATIONS ON IMIDAZOLE DERIVATIVES FOR ANALGESIC ACTIVITY

Sonali Kisan Navale*, Pallavi Kashinath Bhusari, Dipti Shankar Gajabhare, Rutuja Sambhaji Khose

Samrth Institute of Pharmacy, Belhe, Pune, Maharashtra, India.

Article Received on 05 May 2026,
Article Revised on 25 May 2026,
Article Published on 01 June 2026

https://doi.org/10.5281/zenodo.20439533

***Corresponding Author**
Sonali Kisan Navale
Samrth Institute of Pharmacy, Belhe, Pune, Maharashtra, India.

How to cite this Article: Sonali Kisan Navale*, Pallavi Kashinath Bhusari, Dipti Shankar Gajabhare, Rutuja Sambhaji Khose (2026). A Review of Molecular Docking Investigations on Imidazole Derivatives for Analgesic Activity. World Journal of Pharmaceutical Research, 15(11), 596–605.

ABSTRACT

Imidazole derivatives have attracted considerable interest in medicinal chemistry because of their wide range of biological activities, particularly their analgesic effects. Molecular docking has become an essential computational technique for predicting interactions between ligands and biological targets, thereby supporting faster drug discovery. This review highlights recent developments in docking studies of imidazole-based compounds focusing on enzymes involved in pain mechanisms, especially cyclooxygenase (COX). It also discusses structure–activity relationships, binding mechanisms, and pharmacokinetic properties to emphasize the potential of imidazole derivatives as effective analgesic agents. Imidazole derivatives represent an important class of heterocyclic compounds widely explored in medicinal chemistry due to their diverse pharmacological activities. Among these, analgesic activity has gained significant attention because of the need for safer and more effective pain management drugs. Molecular docking has emerged as a powerful computational tool for predicting ligand–protein interactions and guiding drug design. This review focuses on the role of molecular docking in evaluating imidazole derivatives as potential analgesic agents, particularly targeting cyclooxygenase (COX) enzymes. Recent studies demonstrate that imidazole-based compounds exhibit strong binding affinity toward COX-2 receptors, correlating with enhanced analgesic and anti-inflammatory effects. This review highlights the design, docking methodologies, biological evaluation, and future prospects of imidazole derivatives in analgesic drug discovery.

KEYWORDS: Imidazole derivatives; Molecular docking; Analgesic activity; COX inhibitors; Computational studies.

INTRODUCTION

Cyclooxygenase-2 (COX-2), also known as Prostaglandin-endoperoxide synthase 2 (PTGS2), is an enzyme produced by the PTGS2 gene in humans. It is one of the three cyclooxygenase isoforms and plays a crucial role in converting arachidonic acid into prostaglandin H2, an important precursor for prostacyclin involved in inflammatory processes.COX-2 catalyzes the transformation of arachidonic acid (AA) into prostaglandin endoperoxide H2 through a two-step reaction. Initially, a hydrogen atom is removed from carbon 13 of arachidonic acid, followed by the incorporation of two oxygen molecules to form prostaglandin G2 (PGG2). This intermediate is then reduced to prostaglandin H2 (PGH2) at the peroxidase active site. COX-2 exists as a homodimer, with each subunit containing both cyclooxygenase and peroxidase active sites. The produced PGH2 is further metabolized by specific tissue enzymes into various bioactive compounds, including prostaglandins (PGD2, PGE2, PGF2α), prostacyclin (PGI2), and thromboxane A2. However, their clinical use is often associated with adverse effects such as bronchospasm, angioedema, renal impairment, bone marrow suppression, headaches, and dizziness. These limitations have driven the need to develop newer COX-2 inhibitors with improved selectivity and safety profiles. During inflammation, several key bioactive mediators, including prostaglandins (PGD2, PGE2, PGI2, PGF2α) and thromboxane A2, play significant roles. The enzyme phospholipase A2 (PLA2) releases arachidonic acid from membrane phospholipids, which is subsequently converted into PGH2 by COX-1 and COX-2 enzymes. This intermediate is then further processed by specific synthases into active prostaglandins and thromboxane. The level of prostaglandin production largely depends on COX enzyme expression, particularly COX-2, in inflamed tissues. Among these mediators, PGE2 is especially important as it contributes to fever, allergic reactions, tumor progression, and other inflammatory symptoms. Analgesic drugs are used to relieve pain without causing loss of consciousness. Conventional non-steroidal anti-inflammatory drugs (NSAIDs) such as diclofenac and ibuprofen are effective but associated with side effects like gastric irritation and cardiovascular risks. Imidazole is a five-membered heterocyclic ring containing two nitrogen atoms, which contributes to its biological versatility. Imidazole derivatives exhibit a wide range of pharmacological activities including antimicrobial, antifungal, anticancer, anti-inflammatory, and analgesic effects. With the advancement of computational chemistry, molecular docking has become an essential tool in

drug discovery. It helps predict the interaction between drug candidates and biological targets, reducing time and cost associated with experimental screening.

The main objective of this study was to design and evaluate novel imidazole derivatives as potential COX-2 inhibitors for managing inflammatory conditions. A Structure-Activity Relationship (SAR) approach was employed to enhance the potency and selectivity of the compounds, leading to the development of three new derivatives. The introduction of a methylsulfonyl group into the imidazole scaffold was intended to improve binding affinity toward the COX-2 enzyme. To achieve this, molecular docking studies were performed to predict the binding interactions and orientation of the ligands within the COX-2 active site. Molecular dynamics simulations were further conducted to assess the stability and conformational behavior of the protein–ligand complexes over time. Additionally, the MMPBSA method was used to estimate binding free energy, offering insights into interaction energetics. ADMET analysis was also carried out to evaluate pharmacokinetic properties and safety, ensuring the suitability of these compounds as potential drug candidates. This integrated in silico strategy plays a vital role in modern drug discovery by enabling efficient optimization of therapeutic molecules prior to experimental validation. Pain is a multifaceted biological response regulated by biochemical pathways involving inflammatory mediators such as prostaglandins. Cyclooxygenase enzymes (COX-1 and COX-2) are essential in converting arachidonic acid into prostaglandins, making them important targets in pain management. Imidazole, a five-membered heterocyclic ring containing two nitrogen atoms, has been extensively studied due to its strong interaction with biological systems. Advances in computational methods, particularly molecular docking, allow researchers to estimate how ligands bind to target proteins in terms of orientation and affinity. This significantly minimizes the cost and duration of traditional drug development processes.

Despite the availability of various analgesic drugs, limitations such as adverse effects, tolerance, and drug resistance necessitate the development of safer and more effective alternatives. Heterocyclic compounds, particularly imidazole derivatives, have gained attention due to their structural versatility and ability to interact with multiple biological targets. The integration of computational techniques like molecular docking has accelerated drug discovery by predicting ligand–protein interactions and reducing experimental costs.

Imidazole Scaffold and Pharmacological Importance

The imidazole ring serves as a key pharmacophore present in numerous biologically active molecules. It exhibits diverse therapeutic properties, including antimicrobial, antifungal, anticancer, and analgesic effects. Chemical modifications of this ring system can enhance its selectivity and binding strength toward specific biological targets. The imidazole ring is considered a privileged scaffold in medicinal chemistry because of its ability to bind with multiple biological targets. Its structural similarity to the amino acid histidine enables it to participate in enzymatic reactions and receptor binding. The pharmacological importance of the imidazole scaffold lies in its ability to form stable complexes with proteins through hydrogen bonding, electrostatic interactions, and coordination with metal ions. Additionally, the ease of substitution at various positions on the ring allows the design of compounds with improved potency, selectivity, and pharmacokinetic properties. This adaptability makes imidazole derivatives highly valuable in rational drug design.

Molecular Docking in Drug Discovery

Molecular docking is a theoretical computational technique used to predict the preferred orientation of a ligand when it binds to a target protein. It is based on the concept of molecular recognition, where the biological activity of a compound depends on its ability to fit into the binding site of a receptor. The docking process involves the use of algorithms and scoring functions to evaluate binding affinity and interaction energy. The lock-and-key model and induced fit theory are commonly used to explain ligand–protein interactions. Docking not only predicts the binding mode but also helps in identifying key amino acid residues involved in the interaction, thereby facilitating the design of more effective drugs. Molecular docking is a computational approach used to predict how a ligand interacts with a receptor at the molecular level.

Structure–Activity Relationship (SAR)

Structure–activity relationship studies are based on the principle that the biological activity of a compound is directly related to its chemical structure. Changes in functional groups, electronic properties, and steric factors can significantly influence the interaction of a molecule with its target. In imidazole derivatives, substitution at different positions on the ring affects their pharmacological activity. Electron-donating groups generally enhance binding interactions, while lipophilicity influences membrane permeability and bioavailability. Steric factors determine how well a molecule fits into the binding site.

Understanding these relationships helps in optimizing lead compounds and designing more potent analgesic agents.

Presence of electron-donating or electron-withdrawing groups on the imidazole scaffold can alter the electron density of the ring system, thereby influencing its interaction with amino acid residues in the active site of target proteins. Electron-donating groups tend to enhance binding interactions by increasing electron density, which can strengthen hydrogen bonding and π–π interactions. Conversely, electron-withdrawing groups may stabilize the molecule and improve its interaction with polar residues, depending on the nature of the binding site. These electronic effects directly impact the inhibitory activity of imidazole derivatives against enzymes involved in pain pathways.

Steric factors also play a crucial role in SAR, as the size and spatial arrangement of substituents determine how well a molecule can fit into the binding pocket of a protein. Appropriately sized substituents can enhance selectivity and binding efficiency, while excessively bulky groups may hinder proper orientation and reduce activity. Additionally, lipophilicity is an important parameter that influences the ability of the compound to cross biological membranes and reach its target site. An optimal balance between hydrophilicity and lipophilicity is essential for achieving effective analgesic activity.

SAR studies further indicate that substitution at specific positions, such as the N-1 or C-2 positions of the imidazole ring, can significantly alter pharmacological properties. For instance, modifications at these positions may enhance interaction with cyclooxygenase enzymes or ion channels, thereby improving analgesic efficacy. The introduction of aromatic or heterocyclic moieties as substituents can also increase hydrophobic interactions within the binding site, leading to greater stability of the ligand–protein complex.

Target Proteins in Analgesic Activity

Cyclooxygenase-2 (COX-2)

COX-2 is an inducible enzyme associated with inflammation and pain. Selective inhibition of COX-2 is preferred as it minimizes adverse effects compared to non-selective drugs.

Cyclooxygenase-1 (COX-1)

COX-1 is responsible for maintaining normal physiological functions such as protecting the gastric lining. Its inhibition may lead to undesirable side effects.

Analgesic activity involves interaction with several biological targets, including cyclooxygenase enzymes, ion channels, and receptors. Cyclooxygenase enzymes are responsible for the synthesis of prostaglandins, which play a key role in inflammation and pain. Voltage-gated sodium channels are involved in the transmission of nerve impulses, while receptors such as opioid and TRPV1 receptors are associated with pain perception. The interaction of imidazole derivatives with these targets depends on their ability to fit into the binding site and form stable interactions with amino acid residues.

Mechanism of Analgesic Activity

The analgesic activity of imidazole derivatives can be explained through multiple mechanisms at the molecular level. One of the primary mechanisms is the inhibition of enzymes responsible for the production of inflammatory mediators, thereby reducing pain and inflammation. Another mechanism involves the blocking of ion channels, which prevents the transmission of pain signals along nerve fibers. Additionally, interaction with specific receptors can alter neurotransmitter release and modify pain perception. These mechanisms are governed by the principles of ligand–protein interaction and molecular recognition. The mechanism of analgesic activity of imidazole derivatives can be understood through a combination of biochemical, molecular, and pharmacological processes that modulate pain signaling pathways. At the molecular level, pain is primarily mediated by the synthesis and release of inflammatory mediators such as prostaglandins, which are produced from arachidonic acid through the action of cyclooxygenase enzymes. Imidazole derivatives are known to inhibit these enzymes, particularly inducible forms associated with inflammation, thereby reducing the production of prostaglandins and ultimately decreasing pain and inflammation. This enzyme inhibition occurs through the binding of the imidazole moiety to the active site of the enzyme, where it interacts with key amino acid residues via hydrogen bonding and hydrophobic interactions, preventing substrate access and catalytic activity.

Future Perspectives

Future advancements in the field of imidazole-based drug design are expected to focus on the integration of advanced computational techniques such as artificial intelligence, machine learning, and molecular dynamics simulations. These approaches will enhance the accuracy of predicting ligand–protein interactions and improve the efficiency of drug discovery. Furthermore, the development of multi-target drugs and the incorporation of ADME an The use of structure-based drug design is also expected to expand, utilizing high-resolution

protein structures to develop compounds with improved specificity and reduced side effects. In parallel, quantitative structure–activity relationship models will continue to assist in predicting biological activity and guiding structural modifications for enhanced potency. The incorporation of advanced pharmacokinetic prediction tools such as SwissADME will further support the early evaluation of drug-likeness, absorption, distribution, metabolism, and excretion properties, thereby improving the success rate of potential drug candidates.

Future research will also explore novel substitutions on the imidazole ring and the development of hybrid molecules to enhance analgesic activity and selectivity. Additionally, there is growing interest in targeting emerging pain pathways, including neuroinflammatory mediators and cytokine signaling systems, which are particularly relevant in chronic and neuropathic pain conditions. The concept of personalized medicine may also influence future drug design, where computational tools are used to tailor treatments based on individual genetic profiles.

Moreover, there is an increasing emphasis on sustainable and green chemistry approaches in the synthesis of imidazole derivatives to minimize environmental impact. Despite the advancements in computational methods, experimental validation through in vitro and in vivo studies will remain essential to confirm the safety and efficacy of newly designed compounds. Overall, the integration of advanced computational techniques, innovative chemical modifications, and comprehensive biological evaluation is expected to drive the future development of safer and more effective imidazole-based analgesic agents.d toxicity predictions will contribute to the design of safer and more effective analgesic agents.

CONCLUSION

Imidazole derivatives are promising candidates for the development of novel analgesic agents. Molecular docking plays a crucial role in understanding ligand–protein interactions and predicting biological activity. The strong correlation between docking results and experimental findings highlights the importance of computational approaches in modern drug discovery. Further research and clinical validation are required to develop safer and more effective imidazole-based analgesics. Imidazole derivatives represent a promising class of compounds in the development of analgesic drugs due to their unique structural and electronic properties. Theoretical approaches such as molecular docking provide valuable insights into their interaction with biological targets and help in predicting their pharmacological activity. A comprehensive understanding of binding affinity, structure–

activity relationships, and mechanisms of action is essential for the rational design of new drugs. Continued research in this area is likely to lead to the development of novel, safe, and effective analgesic therapies. Imidazole derivatives represent a highly promising class of compounds in the development of novel analgesic agents due to their favorable structural, electronic, and pharmacological properties. Their ability to participate in diverse non-covalent interactions, coupled with their adaptability as a privileged scaffold, makes them suitable candidates for targeting multiple proteins involved in pain and inflammation. Theoretical approaches such as molecular docking have significantly enhanced the understanding of ligand–protein interactions, enabling the prediction of binding affinity, orientation, and stability of imidazole-based compounds within biological targets.

In addition to docking studies, the integration of in silico pharmacokinetic evaluation tools such as SwissADME has further strengthened the drug discovery process. SwissADME provides a comprehensive assessment of absorption, distribution, metabolism, and excretion (ADME) properties, along with drug-likeness parameters based on established rules such as Lipinski's rule of five. Theoretical evaluation of imidazole derivatives using such tools helps in identifying compounds with optimal bioavailability, good gastrointestinal absorption, and minimal toxicity, thereby improving the chances of clinical success. Parameters such as lipophilicity, water solubility, and pharmacokinetic profiles play a crucial role in determining the overall efficacy of potential analgesic agents.

Another critical aspect in molecular docking studies is protein preparation, which ensures the accuracy and reliability of docking results. Protein preparation involves several theoretical steps, including the removal of water molecules, addition of missing hydrogen atoms, correction of bond orders, assignment of proper ionization states, and energy minimization of the protein structure. These steps are essential to achieve a biologically relevant conformation of the target protein and to accurately simulate the interaction between the ligand and the active site. Proper preparation of the protein ensures that docking simulations reflect realistic binding scenarios, thereby enhancing the predictive power of computational studies. Overall, the combination of imidazole chemistry, molecular docking, ADME prediction through SwissADME, and meticulous protein preparation provides a robust theoretical framework for rational drug design. These integrated approaches not only facilitate the identification of potent and selective analgesic compounds but also reduce the time and cost associated with experimental drug development. Continued advancements in computational methodologies

are expected to further refine these processes and contribute to the discovery of safer and more effective analgesic therapies in the future.

REFERENCES

1. Kharb R, Sharma PC, Yar MS. Pharmacological significance of imidazole scaffold: a review. J. Enzyme. Inhib. Med. Chem., 2011; 26(1): 1–21.
2. Almasirad A, Mousavi Z, Tajik M, Assarzadeh MJ, Shafiee A. Synthesis, analgesic and anti-inflammatory activities of new imidazole derivatives. DARU J. Pharm. Sci., 2014; 22: 22.
3. El-Sayed WA, El-Essawy FA, Ali OM. Design, synthesis and analgesic activity of some novel imidazole derivatives. Eur. J. Med. Chem., 2012; 54: 507–513.
4. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking. J. Comput. Chem., 2010; 31(2): 455–461.
5. Morris GM, Huey R, Lindstrom W, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem., 2009; 30(16): 2785–2791.
6. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery. Adv. Drug Deliv. Rev., 2001; 46(1–3): 3–26.
7. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Am. J. Med. 1998; 104(3A): 2S–8S.
8. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J., 2004; 18(7): 790–804.
9. Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Pharmacology. 7th ed. Elsevier; 2012.
10. Noor A, Qazi NG, Nadeem H, et al. Synthesis, characterization, antimicrobial and docking studies of benzimidazole derivatives. BMC Chem. 2017; 11: 31.
11. Hassan AA, Mahdi MF. Molecular docking study of imidazole derivatives as COX-2 inhibitors. Asian J. Pharm. Sci., 2020; 15(3): 321–330.
12. Muheyuddeen G, Khan MY, Ahmad T, et al. Design, synthesis and biological evaluation of imidazole derivatives as analgesic agents. Sci. Rep., 2024; 14: 72399.
13. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery. Nat Rev Drug Discov. 2004; 3(11): 935–949.

14. Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des., 2011; 7(2): 146–157.
15. Abdel-Aziz AA, El-Azab AS, Eltahir KEH, et al. Design, synthesis and biological evaluation of imidazole derivatives as anti-inflammatory and analgesic agents. Eur. J. Med. Chem., 2011; 46(12): 5615–5621.